Literature DB >> 27747054

Systemic therapy for echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase non-small cell lung cancer brain metastases.

Jenny Guo1, Ralph Zinner2, Nicholas G Zaorsky3, Wei Guo4, Bo Lu5.   

Abstract

Entities:  

Year:  2016        PMID： 27747054      PMCID： PMC5059245          DOI： 10.21037/jtd.2016.09.09

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  16 in total

1.  Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

Authors:  Daniel B Costa; Alice T Shaw; Sai-Hong I Ou; Benjamin J Solomon; Gregory J Riely; Myung-Ju Ahn; Caicun Zhou; S Martin Shreeve; Paulina Selaru; Anna Polli; Patrick Schnell; Keith D Wilner; Robin Wiltshire; D Ross Camidge; Lucio Crinò
Journal:  J Clin Oncol       Date:  2015-01-26       Impact factor: 44.544

Review 2.  Targeting brain metastases in ALK-rearranged non-small-cell lung cancer.

Authors:  Isabella Zhang; Nicholas G Zaorsky; Joshua D Palmer; Ranee Mehra; Bo Lu
Journal:  Lancet Oncol       Date:  2015-10       Impact factor: 41.316

3.  Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers.

Authors:  Dae Ho Lee; Ji-Youn Han; Hong Gi Lee; Jae Jin Lee; Eun Kyoung Lee; Hyae Young Kim; Hark Kyun Kim; Eun Kyung Hong; Jin Soo Lee
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

4.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

5.  Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.

Authors:  James W Welsh; Ritsuko Komaki; Arya Amini; Mark F Munsell; Wyatt Unger; Pamela K Allen; Joe Y Chang; Jeffrey S Wefel; Susan L McGovern; Linda L Garland; Su S Chen; Jamie Holt; Zhongxing Liao; Paul Brown; Erik Sulman; John V Heymach; Edward S Kim; Baldassarre Stea
Journal:  J Clin Oncol       Date:  2013-01-22       Impact factor: 44.544

6.  Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

Authors:  Benjamin J Solomon; Federico Cappuzzo; Enriqueta Felip; Fiona H Blackhall; Daniel B Costa; Dong-Wan Kim; Kazuhiko Nakagawa; Yi-Long Wu; Tarek Mekhail; Jolanda Paolini; Jennifer Tursi; Tiziana Usari; Keith D Wilner; Paulina Selaru; Tony S K Mok
Journal:  J Clin Oncol       Date:  2016-03-28       Impact factor: 44.544

Review 7.  Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm.

Authors:  Elizabeth R Gerstner; Robert L Fine
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

8.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245

9.  Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Authors:  Alice T Shaw; Leena Gandhi; Shirish Gadgeel; Gregory J Riely; Jeremy Cetnar; Howard West; D Ross Camidge; Mark A Socinski; Alberto Chiappori; Tarek Mekhail; Bo H Chao; Hossein Borghaei; Kathryn A Gold; Ali Zeaiter; Walter Bordogna; Bogdana Balas; Oscar Puig; Volkmar Henschel; Sai-Hong Ignatius Ou
Journal:  Lancet Oncol       Date:  2015-12-19       Impact factor: 41.316

10.  Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.

Authors:  Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Jürgen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Santosh Sutradhar; Siyu Li; Tomasz Szczudlo; Alejandro Yovine; Alice T Shaw
Journal:  Lancet Oncol       Date:  2016-03-11       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.